Operation Warp Speed

In the AI Story

The program's structure followed conventional pharmaceutical procurement logic: the government paid for research and committed to purchase vaccine doses, in exchange for eventual delivery of vaccines. The intellectual property remained with the private firms. The pricing of subsequent vaccine doses was determined by the firms, not by the public investor. The commercial returns from global vaccine sales — which extended far beyond the initial US purchase commitments — flowed entirely to private shareholders.

The scale of public investment relative to commercial returns was asymmetric in ways that became politically visible during the pandemic. Moderna's COVID-19 vaccine revenue in 2021–2022 exceeded thirty-six billion dollars — multiples of the public investment. Pfizer's combined BioNTech vaccine revenue reached similar scale. The public investor — the US taxpayer — received no equity stake in these outcomes, no royalty stream on global sales, and no pricing authority over subsequent commercial deployment.

The political response produced proposals for institutional reform that largely did not pass. Proposals for conditional pricing (requiring reasonable prices on publicly funded therapeutics), equity stakes in companies receiving emergency funding, and windfall taxation of pandemic profits circulated but did not achieve legislative implementation. The institutional architecture that enabled the Warp Speed arrangement remained intact.

The AI parallel is structural. The current public investments in AI development — through the National AI Research Resource, CHIPS Act semiconductor support, EU AI Factories — are following the Warp Speed template: public capital absorbing commercial risk while private firms retain commercial returns. The mechanisms for public participation in the upside that Mazzucato's framework prescribes have not been implemented, even as the scale of expected returns dwarfs the pharmaceutical precedent.

Origin

Operation Warp Speed was established in May 2020 under the Trump administration in response to the COVID-19 pandemic. The program continued under the Biden administration with modifications to distribution and pricing elements. Its structural arrangement drew on existing pharmaceutical procurement frameworks without introducing mechanisms for public participation in upside returns.

Mazzucato's critique of the Warp Speed arrangement, developed in her 2020 IIPP working paper The COVID-19 Response, applied her entrepreneurial-state framework to the specific emergency context, arguing that the public investor's patient funding of mRNA research over three decades should have entitled the public to participation in the commercial returns.

Key Ideas

$18 billion in public investment. The scale of Warp Speed's public contribution to vaccine development.

Risk absorption by public capital. The program eliminated commercial risk for private firms during development.

Private IP retention. Intellectual property and commercial returns remained with private firms.

Political visibility without institutional response. The arrangement produced proposals for reform but no structural change.

AI template. Current AI public investment programs follow the Warp Speed arrangement.